X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare ALEMBIC PHARMA with Aventis Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALEMBIC PHARMA vs SANOFI INDIA - Comparison Results

SANOFI INDIA 
   Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALEMBIC PHARMA SANOFI INDIA ALEMBIC PHARMA/
SANOFI INDIA
 
P/E (TTM) x 27.4 40.3 67.9% View Chart
P/BV x 5.5 8.7 63.5% View Chart
Dividend Yield % 0.6 1.0 59.3%  

Financials

 ALEMBIC PHARMA   SANOFI INDIA
EQUITY SHARE DATA
    ALEMBIC PHARMA
Mar-18
SANOFI INDIA
Dec-16
ALEMBIC PHARMA/
SANOFI INDIA
5-Yr Chart
Click to enlarge
High Rs6454,560 14.1%   
Low Rs4704,400 10.7%   
Sales per share (Unadj.) Rs166.11,028.5 16.1%  
Earnings per share (Unadj.) Rs21.9129.0 17.0%  
Cash flow per share (Unadj.) Rs27.5186.0 14.8%  
Dividends per share (Unadj.) Rs4.0068.00 5.9%  
Dividend yield (eoy) %0.71.5 47.3%  
Book value per share (Unadj.) Rs117.8753.6 15.6%  
Shares outstanding (eoy) m188.5223.03 818.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.44.4 77.1%   
Avg P/E ratio x25.534.7 73.3%  
P/CF ratio (eoy) x20.324.1 84.2%  
Price / Book Value ratio x4.75.9 79.6%  
Dividend payout %18.352.7 34.6%   
Avg Mkt Cap Rs m105,090103,174 101.9%   
No. of employees `000NA3.6 0.0%   
Total wages/salary Rs m6,2283,592 173.4%   
Avg. sales/employee Rs ThNM6,537.7-  
Avg. wages/employee Rs ThNM991.4-  
Avg. net profit/employee Rs ThNM819.8-  
INCOME DATA
Net Sales Rs m31,30823,686 132.2%  
Other income Rs m70708 9.9%   
Total revenues Rs m31,37824,394 128.6%   
Gross profit Rs m6,4315,281 121.8%  
Depreciation Rs m1,0551,313 80.3%   
Interest Rs m3415 226.7%   
Profit before tax Rs m5,4134,661 116.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m-810-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,2041,691 71.2%   
Profit after tax Rs m4,1282,970 139.0%  
Gross profit margin %20.522.3 92.1%  
Effective tax rate %22.236.3 61.3%   
Net profit margin %13.212.5 105.2%  
BALANCE SHEET DATA
Current assets Rs m18,24715,673 116.4%   
Current liabilities Rs m11,2356,678 168.2%   
Net working cap to sales %22.438.0 59.0%  
Current ratio x1.62.3 69.2%  
Inventory Days Days8676 112.6%  
Debtors Days Days6122 275.0%  
Net fixed assets Rs m20,0358,098 247.4%   
Share capital Rs m377230 163.7%   
"Free" reserves Rs m21,82417,088 127.7%   
Net worth Rs m22,20117,356 127.9%   
Long term debt Rs m5,0000-   
Total assets Rs m39,41125,400 155.2%  
Interest coverage x160.2311.7 51.4%   
Debt to equity ratio x0.20-  
Sales to assets ratio x0.80.9 85.2%   
Return on assets %10.611.8 89.9%  
Return on equity %18.617.1 108.7%  
Return on capital %19.726.9 73.2%  
Exports to sales %46.424.5 189.6%   
Imports to sales %10.528.0 37.5%   
Exports (fob) Rs m14,5355,801 250.6%   
Imports (cif) Rs m3,2886,627 49.6%   
Fx inflow Rs m14,7227,145 206.0%   
Fx outflow Rs m7,0266,846 102.6%   
Net fx Rs m7,696299 2,573.8%   
CASH FLOW
From Operations Rs m3,1243,226 96.8%  
From Investments Rs m-8,844-1,555 568.7%  
From Financial Activity Rs m5,026-1,818 -276.5%  
Net Cashflow Rs m-693-147 471.6%  

Share Holding

Indian Promoters % 74.1 0.0 -  
Foreign collaborators % 0.0 60.4 -  
Indian inst/Mut Fund % 2.9 14.4 20.1%  
FIIs % 9.1 14.6 62.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 13.9 10.5 132.4%  
Shareholders   49,328 15,184 324.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALEMBIC PHARMA With:   JUBILANT LIFE SCIENCES  PANACEA BIOTECH  WOCKHARDT LTD.  ABBOTT INDIA  PLETHICO PHARMA  

Compare ALEMBIC PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Recovers after Crashing Over 1000 Points; DHFL Tanks 50%(01:30 pm)

Stock markets in India plunged in the afternoon session today. The BSE Sensex recovered after tanking 1,000 points in intra-day deals.

Related Views on News

ALEMBIC PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 42.6% (Quarterly Result Update)

Jul 30, 2018 | Updated on Jul 30, 2018

For the quarter ended June 2018, ALEMBIC PHARMA has posted a net profit of Rs 904 m (up 42.6% YoY). Sales on the other hand came in at Rs 9 bn (up 33.1% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

SANOFI INDIA Announces Quarterly Results (1QFY19); Net Profit Up 35.1% (Quarterly Result Update)

Jul 27, 2018 | Updated on Jul 27, 2018

For the quarter ended June 2018, SANOFI INDIA has posted a net profit of Rs 996 m (up 35.1% YoY). Sales on the other hand came in at Rs 7 bn (up 13.8% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

Is It the Right Time to Buy Pharma Stocks Now?(The 5 Minute Wrapup)

Sep 12, 2018

Is the pharma sector poised for a comeback? Is the worst over? I believe so.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

Investors Are Redeeming From Equity Mutual Funds Now. Should You?(Outside View)

Sep 12, 2018

PersonalFN elucidates if you should redeem from equity mutual fund now, and the approach to follow before you decide to sell mutual funds.

Are You Blindly Investing In Equities? Read This...(Outside View)

Sep 11, 2018

PersonalFN explains how blindly investing in equities can prove hazardous to your wealth and health.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ALEMBIC PHARMA SHARE PRICE


Sep 21, 2018 03:37 PM

TRACK ALEMBIC PHARMA

  • Track your investment in ALEMBIC PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALEMBIC PHARMA

ALEMBIC PHARMA 8-QTR ANALYSIS

COMPARE ALEMBIC PHARMA WITH

MARKET STATS